Literature DB >> 12136063

Prevalence and clinical characteristics of migraine in France.

P Henry1, J P Auray, A F Gaudin, J F Dartigues, G Duru, M Lantéri-Minet, C Lucas, A Pradalier, G Chazot, A El Hasnaoui.   

Abstract

OBJECTIVE: To determine the prevalence and clinical features of migraine and related headache types in France.
METHODS: The authors recruited a population of subjects with headache representative of the national population using a stratified sampling method. They screened 10,585 subjects aged 15 and older who were representative of the general population. They identified 1,486 of these as having headaches, and these subjects were subsequently interviewed for information on clinical features, natural history, and functional impact of headache. The authors categorized subjects based on the International Headache Society (IHS) classification and assessed disability using the MIDAS questionnaire.
RESULTS: The authors found a standardized prevalence for migraine (IHS categories 1.1 and 1.2) of 7.9% (11.2% for women and 4.0% for men) and 9.1% for migrainous disorder (IHS category 1.7). Migraine attacks were associated with a considerable degree of handicap in activities of daily living, with a MIDAS grade distribution of 74.7% (grade 1), 13.3% (grade 2), 7.7% (grade 3), and 4.3% (grade 4). The prevalence of migraine with MIDAS grade 3 or 4 was 1.6%.
CONCLUSIONS: The prevalence of migraine (IHS categories 1.1 and 1.2) in France is 7.9%, and that of total migraine is 17.0%; this does not seem to have evolved over the past 10 years.

Entities:  

Mesh:

Year:  2002        PMID: 12136063     DOI: 10.1212/wnl.59.2.232

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

Review 1.  Headache in school children: prevalence and risk factors.

Authors:  Andreas Straube; Florian Heinen; Friedrich Ebinger; Rüdiger von Kries
Journal:  Dtsch Arztebl Int       Date:  2013-11-29       Impact factor: 5.594

2.  [Alimentary trigger factors that provoke migraine and tension-type headache].

Authors:  J Holzhammer; C Wöber
Journal:  Schmerz       Date:  2006-04       Impact factor: 1.107

Review 3.  Headache in school children: is the prevalence increasing?

Authors:  Lucia Albers; Rüdiger von Kries; Florian Heinen; Andreas Straube
Journal:  Curr Pain Headache Rep       Date:  2015-03

Review 4.  [Non-alimentary trigger factors of migraine and tension-type headache].

Authors:  J Holzhammer; C Wöber
Journal:  Schmerz       Date:  2006-06       Impact factor: 1.107

5.  Is iron-deficiency anemia associated with migraine? Is there a role for anxiety and depression?

Authors:  Gülsüm Emel Pamuk; Mehmet Şerif Top; Mehmet Şevki Uyanık; Hilal Köker; Mustafa Akker; Recep Ak; Ömer Atalay Yürekli; Yahya Çelik
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

6.  Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey.

Authors:  Ann Christine Lyngberg; Birthe K Rasmussen; Torben Jørgensen; Rigmor Jensen
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 7.  Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.

Authors:  Paul L McCormack; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.

Authors:  André Pradalier; Jean-Paul Auray; Abdelkader El Hasnaoui; Kazem Alzahouri; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lantéri-Minet; Christian Lucas; Guy Chazot; Anne-François Gaudin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Prevalence of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andree
Journal:  J Headache Pain       Date:  2010-05-16       Impact factor: 7.277

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.